Modipafant

• Description :

  Modipafant (UK-80067), the (+) -enantiomer of UK-74505, is a potent, orally active, and selective platelet-activating factor (PAF) antagonist. Modipafant exhibits approximately double the intrinsic potency of UK-74505[1][2].

• Product Name Alternative :

  UK-80067

• UNSPSC :

  12352005

• Target :

  Platelet-activating Factor Receptor (PAFR)

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/modipafant.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=C(C2=CC=C(N3C(C)=NC4=C3C=CN=C4)C=C2)NC(C)=C(C(NC5=NC=CC=C5)=O)[C@H]1C6=CC=CC=C6Cl)OCC

• Molecular Formula :

  C34H29ClN6O3

• Molecular Weight :

  605.09

• References & Citations :

  [1]Kuitert LM, et al. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med. 1995;151 (5) :1331-1335.|[2]Jezequel SG, et al, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man. Xenobiotica. 1996;26 (9) :963-975.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [122957-06-6]